23.09.2015 • NewsDede WillamsfertilizerYara International

Yara to Sell European CO2 Business to Praxair

Norwegian fertilizer group Yara International has signed a non-binding agreement to sell its European CO2 to industrial gases business to Praxair for €218 million.

The deal set to close in the first quarter of 2016 will also see the Norwegian company transfer its remaining 34% stake in the Yara Praxair Holding joint venture to its industrial gases partner for around €94 million.

“The CO2 business has been an attractive and long-standing part of Yara's portfolio, but remains a relatively small part of the broader industrial gas industry, and where Praxair is well positioned to create additional value,” said Svein Tore Holsether, CEO of Yara International.

Praxair CEO Steve Angel said the acquired business will complement his company’s industrial gases activities in Europe and will also enhance the US group’s presence in non-cyclical segments such as food and beverage.

In 2014, Yara’s European CO2 business with revenues of €112 million sold around 850,000 t/y of liquid CO2 and 50,000 t of dry ice, primarily to the food and beverage industries.

The company operates five CO2 liquefaction plants, three large CO2 shipping vessels, seven shipping terminals and six dry ice production facilities across the UK, Ireland, Scandinavia, Northern Europe and Italy.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.